Great News! Congen Pharma Awarded a US Patent in 2025!
Publish Time:
2025-01-15
At the start of 2025, Congen Pharma achieved remarkable success!
Its innovative EMPHASES® liquid-phase peptide synthesis technology received a US patent authorization, No. US 12,172,946 B2.
Technological Innovation and Advantages
EMPHASES ® The innovative liquid-phase peptide synthesis technology uses a liquid carrier to replace the traditional solid-phase resin, realizing liquid-liquid reaction. This not only improves the reaction speed, shortens the reaction time, and improves the synthesis efficiency; it also reduces the amount of amino acids, condensing agents, and solvents used, reducing three wastes emissions and effectively controlling costs.
Compared with the traditional solid-phase synthesis method, it provides a more efficient, environmentally friendly, scalable, and economical solution. To date, it has obtained 5 Chinese invention patents, 1 US patent, and 1 Japanese patent.
Widely Used
In the pharmaceutical field, EMPHASES ® can efficiently synthesize drug peptides, such as Tirzepatide, Survodutide, Retatrutide, Mazdutide, etc.
In the cosmetics field, it can synthesize classic beauty peptides and help develop new raw materials, such as Acetyl Hexapeptide-8, Palmitoyl Tetrapeptide-7, anti-aging cyclic peptides, etc.
Looking to the Future
With the rapid growth of the global market for drug peptides and beauty peptides, EMPHASES ® innovative liquid-phase peptide synthesis technology has broad prospects. In the future, Congen Pharma will adhere to its mission, forge ahead, and make sustainable and affordable peptides benefit human beauty and health!
Relevant Information
